John F. Crowley - 05 Jan 2022 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
Chairman & CEO, Director
Signature
/s/ Christian Formica, Attorney-in-Fact
Issuer symbol
FOLD
Transactions as of
05 Jan 2022
Net transactions value
-$774,119
Form type
4
Filing time
07 Jan 2022, 16:20:26 UTC
Previous filing
04 Jan 2022
Next filing
13 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Sale $774,119 -63,543 -8.8% $12.18 655,131 05 Jan 2022 Direct F1, F2, F3
holding FOLD Common Stock 64,895 05 Jan 2022 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 Comprised of 46,910 shares received from the 2019 PRSU grant, awarded for exceeding the Galafold revenue goal for the applicable measurement period, and 16,333 shares received from the 2018 annual grant, the receipt of which were deferred by Mr. Crowley until January 1, 2022.
F3 This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.95 to $12.59 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the reported transactions, Mr. Crowley also has approximately 403,000 options outstanding and exercisable at various strike prices.